October 8, 2020 5:34pm

There is just too much speculation concerning “our” country’s issues impacting share pricing

Pre-open indication results: 5 HITs and 0 MISS

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't.

Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed UP +122.05 points (+0.43%), the S&P closed UP +27.38 points (+0.80%) while the Nasdaq closed UP +56.38 points (+0.50%)

 

Henry’omics:

Indexes rose in volatile trading.

A note to traders, Biostage (BSTG) – one (1) share traded took the share price down -$0.09 to $1.51 and the “pumper” came in and bought 351 shares to stabilize the pricing.

  • Leading back to, forward and onto – my “zombie” company profile!

 

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: gravity is a force as risks weigh on volatility … https://www.regmedinvestors.com/articles/11580

 

From this a.m.’s Data Docket, “the latest U.S. weekly jobless claims data showed an additional 840,000 Americans filing for unemployment benefits for the first time.”

 

Pre-open indications: 5 HITs < Biostage (BSTG -$0.00), BUY: SELL into Strength - CRISPR Therapeutics (CRSP -$2.29), Intellia Therapeutics (NTLA -$0.84), Fate Therapeutics (FATE +$0.94), Precigen (PGEN +$0.03) and 0 MISS

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions 

  • Thursday opened positive at 21/13 and 1 flat, strayed negative at the mid-day at 16/18 and 1 flat, closing positive at 18/14 and 3 flats;
  • Wednesday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 28/5 and 2 flats, closing positive at 26/7 and 2 flats;
  • Tuesday opened positive at 17/15 and 2 flats, stayed positive at the mid-day at 21/13 and 1 flat, closing negative at 11/23 and 1 flat;
  • Monday opened positive at 31/3 and 1 flat, stayed positive at the mid-day at 33/1 and 1 flat, closing positive at 33/1 and 1 flat;

 

Key metrics:

  • Sector volume was the usual LOW with 5 of the 18-upside having higher than the 3-month average volume with the increased volume of 5 of 14-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 18-upside were +0.17% (MESO) to +7.09% (BLCM) while the 14-downside ranges from -0.16% (AXGN) to -3.53% (NTLA);

 

Hammered in today’s market:

  • CRISPR Therapeutics (CRSP), Global Blood Therapeutics (GBT), Intellia Therapeutics (NTLA), ReNeuron (RENE.L), Intellia Therapeutics (NTLA) to name 5 of the 14 declining of the 35 covered

Jumping with share pricing momentum:

  • Sage Therapeutics (SAGE), Alnylam Pharmaceuticals (ALNY), Cellectis SA (CLLS), Regenxbio (RGNX), Fate Therapeutics (FATE) to name 5 of the 18 inclining of the 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +0.28% and XBI closed up +0.45%
  • Wednesday, the IBB closed up +2.26% and XBI closed up +3.20%
  • Tuesday, the IBB closed down -1.21% and XBI closed down -0.79%
  • Monday, the IBB closed up +4.26% and XBI closed up +4.94%

 

Thursday’s (10 of 18) incliners:

  • Sage Therapeutics (SAGE +$1.99 after Wednesday’s +$1.42 and Tuesday’s +3.97);
  • Fate Therapeutics (FATE +$0.94 after Wednesday’s +$2.48, Tuesday’s -$0.33 and Monday’s +$3.80),
  • Cellectis SA (CLLS +$0.95);;
  • Regenxbio (RGNX +$0.94);
  • Alnylam Pharmaceuticals (ALNY +$0.64 after Wednesday’s +$2.14, Tuesday’s +$1.26 and Monday’s+$6.32),
  • Brainstorm Cell Therapeutics (BCLI +$0.72);
  • Voyager therapeutics (VYGR +$0.48);
  • Ionis Pharmaceuticals (IONS +$0.42 after Wednesday’s +$1.12 and Tuesday’s -$2.28);
  • Bellicum Pharmaceuticals (BLCM +$0.46);
  • Vericel (VCEL +$0.26);

Thursday’s (10 of 14) decliner:

  • CRISPR Therapeutics (CRSP -$2.29 after Wednesday’s +$9.96, Tuesday’s +$0.97 and Monday’s +$7.08);
  • Global Blood Therapeutics (GBT -$2.22 after Wednesday’s +$1.96, Tuesday’s +$0.02 and Monday’s +$4.79);
  • BioLife Solutions (BLFS -$0.83 after Wednesday’s -$0.09 and Tuesday’s +$0.46);
  • Intellia Therapeutics (NTLA -$0.84 after Wednesday’s +$2.77, Tuesday’s +$0.24 and Monday’s +$1.94);
  • ReNeuron (RENE.L -$0.90);
  • uniQure NV (QURE -$0.37 after Wednesday’s -$0.14);
  • Editas Medicine (EDIT -$0.33);
  • Sangamo Therapeutics (SGMO -$0.29);
  • Solid Bioscience (SLDB -$0.13 after Wednesday’s -$0.27 and Tuesday’s -$0.38);
  • Caladrius Bioscience (CLBS -$0.06)

Closing flat –3 – Biostage (BSTG), bluebird bio (BLUE) and Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Thursday’s percentage (%) of the 18-upside were +0.17% (MESO) to +7.09% (BLCM) while the 14-downside ranges from -0.16% (AXGN) to -3.53% (NTLA);
  • Wednesday’s percentage (%) of the 26-upside were +0.54% (CLBS) to +13.18% (NTLA) while the 9-downside ranges from -0.31% (BLFS) to -6.18% (SLDB);
  • Tuesday’s percentage (%) of the 11-upside were +0.03% (GBT) to +6.60% (SAGE) while the 23-downside of -0.07% (BLUE) to -8% (SLDB);
  • Monday’s percentage (%) of the 33-upside were +0.52% (RENE.L) to +13.64% (SLDB) while the 1-downside of -0.30% (MDXG);

 

Sentiment and a few daily indicators:

Speaker Nancy Pelosi dampened sentiment around a potential smaller coronavirus aid package.

Infection cases <Million>:

  • Thursday 7.55 M cases
  • Wednesday 7.5 M cases
  • Tuesday 7.45 M cases
  • Monday 7.44 M cases

Thursday’s death rate totaled 211,844 after Wednesday’s 210,918, Tuesday’s 210,195, Monday’s 210.013, Friday’s 207,818 and last Thursday’s 206,036 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Thursday: 5 out of the 18-upside had higher than the 3-month average volume;
  • Wednesday: 8 out of the 26-upside had higher than the 3-month average volume;
  • Tuesday: 3 out of the 11-upside had higher than the 3-month average volume;
  • Monday: 12 out of the 33-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -1.66 points or -5.92% at 26.40
  • Wednesday was down -1.42 points or -4.82% at 28.06
  • Tuesday was up +0.10 points or +0.36% at 28.06
  • Monday was up +0.33 points or +1.19% at 27.96

Downside volume:

  • Thursday: 5 out of the 14-downside had higher than the 3-month average volume;
  • Wednesday: 0 out of the 9-downside had higher than the 3-month average volume;
  • Tuesday: 4 out of the 23-downside had higher than the 3-month average volume;
  • Monday: 1 out of the 1-downside had higher than the 3-month average volume;

 

October, the first month <October> of Q4 …

Thursday closed positive with 18 advancers, 14 decliners and 3 flats

Wednesday closed positive with 26 advancers, 9 decliners and 2 flats 

Tuesday closed negative with 11 advancers, 23 decliners and 1 flat 

Monday (10/5) closed positive with 33 advancers, 1 declined and 1 flat 

Friday closed negative with 8 advancers, 26 decliners and 1 flat 

Thursday (10/1) closed negative with 21 advancers, 12 decliners and 2 flats

 

The Bottom Line: As I stated yesterday and the day before, “profit now, a market storm is brewing”.

Pre-open indications are right again … it’s getting to be a constant!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.